Dr. Skoog summarises SWEDEPAD trials: implications for PAD care

Following his presentation at PVI 2025, Dr. Per Skoog highlights the main takeaways from the SWEDEPAD I and II trials for everyday practice. 

SWEDEPAD I focused on patients with chronic limb-threatening ischemia (CLTI), while SWEDEPAD II included patients with intermittent claudication. These landmark studies challenge the effectiveness of drug-eluting devices, showing no significant improvement in patient-centered outcomes such as amputation rates for CLTI patients or quality of life for claudicants. 

In addition, SWEDEPAD I revealed a slight early increase in amputations in the drug-eluting arm, and SWEDEPAD II found higher 5-year mortality in the same group.

Bottom line from these trials: drug-eluting devices did not improve outcomes compared with non-coated options. 

Discover in the interview how this finding can inform everyday PAD care!


Watch our webinar replay about SWEDEPAD II to find out more!